- Home
- CRT vs IMMX Comparison
CRT vs IMMX Comparison
Compare CRT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- IMMX
- Stock Information
- Founded
- CRT 1991
- IMMX 2014
- Country
- CRT United States
- IMMX United States
- Employees
- CRT N/A
- IMMX N/A
- Industry
- CRT Oil & Gas Production
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CRT Energy
- IMMX Health Care
- Exchange
- CRT Nasdaq
- IMMX Nasdaq
- Market Cap
- CRT 65.1M
- IMMX 61.1M
- IPO Year
- CRT 1992
- IMMX 2021
- Fundamental
- Price
- CRT $8.69
- IMMX $2.27
- Analyst Decision
- CRT
- IMMX Strong Buy
- Analyst Count
- CRT 0
- IMMX 1
- Target Price
- CRT N/A
- IMMX $7.00
- AVG Volume (30 Days)
- CRT 27.7K
- IMMX 258.8K
- Earning Date
- CRT 01-01-0001
- IMMX 08-08-2025
- Dividend Yield
- CRT 10.25%
- IMMX N/A
- EPS Growth
- CRT N/A
- IMMX N/A
- EPS
- CRT 0.92
- IMMX N/A
- Revenue
- CRT $6,559,820.00
- IMMX N/A
- Revenue This Year
- CRT N/A
- IMMX N/A
- Revenue Next Year
- CRT N/A
- IMMX N/A
- P/E Ratio
- CRT $9.45
- IMMX N/A
- Revenue Growth
- CRT N/A
- IMMX N/A
- 52 Week Low
- CRT $8.46
- IMMX $1.26
- 52 Week High
- CRT $13.31
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- CRT 35.33
- IMMX 40.03
- Support Level
- CRT $8.46
- IMMX $2.15
- Resistance Level
- CRT $8.87
- IMMX $2.50
- Average True Range (ATR)
- CRT 0.24
- IMMX 0.22
- MACD
- CRT -0.01
- IMMX -0.06
- Stochastic Oscillator
- CRT 19.33
- IMMX 15.00
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.